Parallel Advisors, LLC Biomarin Pharmaceutical Inc Transaction History

Parallel Advisors, LLC

$4.31 Billion
Q1 2025

A detailed history of Parallel Advisors, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Parallel Advisors, LLC holds 1,335 shares of BMRN stock, worth $83,757. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,335

Previous 675 97.78%

Holding current value

$83,757

Previous $44,000 113.64%

% of portfolio

0.0%

Previous 0.0%

34 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 07, 2025	BUY	$61.25 - $72.83 $40,425 - $48,067	660 Added 97.78%	1,335 $94,000
Q4 2024 Feb 10, 2025	SELL	$61.93 - $70.49 $24,462 - $27,843	-395 Reduced 36.92%	675 $44,000
Q3 2024 Nov 13, 2024	SELL	$69.02 - $93.84 $73,437 - $99,845	-1,064 Reduced 49.86%	1,070 $75,000
Q2 2024 Aug 08, 2024	SELL	$74.43 - $92.22 $17,342 - $21,487	-233 Reduced 9.84%	2,134 $175,000
Q1 2024 May 06, 2024	BUY	$83.81 - $99.0 $14,163 - $16,731	169 Added 7.69%	2,367 $206,000
Q4 2023 Feb 09, 2024	SELL	$76.22 - $98.51 $11,737 - $15,170	-154 Reduced 6.55%	2,198 $211,000
Q3 2023 May 20, 2024	SELL	$85.07 - $94.48 $260,484 - $289,297	-3,062 Reduced 56.56%	2,352 $208,000
Q3 2023 Nov 13, 2023	SELL	$85.07 - $94.48 $260,484 - $289,297	-3,062 Reduced 56.56%	2,352 $208,000
Q2 2023 May 20, 2024	SELL	$86.68 - $100.3 $52,354 - $60,581	-604 Reduced 10.04%	5,414 $469,000
Q2 2023 Aug 04, 2023	SELL	$86.68 - $100.3 $52,354 - $60,581	-604 Reduced 10.04%	5,414 $469,000
Q1 2023 May 20, 2024	BUY	$87.74 - $117.27 $320,338 - $428,152	3,651 Added 154.25%	6,018 $585,000
Q1 2023 Apr 25, 2023	BUY	$87.74 - $117.27 $91,776 - $122,664	1,046 Added 21.04%	6,018 $585,000
Q4 2022 Feb 03, 2023	BUY	$80.93 - $108.63 $35,528 - $47,688	439 Added 9.68%	4,972 $514,000
Q3 2022 Nov 10, 2022	BUY	$82.16 - $96.94 $270,224 - $318,835	3,289 Added 264.39%	4,533 $384,000
Q2 2022 Aug 01, 2022	BUY	$71.48 - $86.85 $2,072 - $2,518	29 Added 2.39%	1,244 $103,000
Q1 2022 Apr 28, 2022	SELL	$74.28 - $92.69 $19,461 - $24,284	-262 Reduced 17.74%	1,215 $95,000
Q4 2021 Jan 20, 2022	BUY	$71.72 - $91.47 $53,790 - $68,602	750 Added 103.16%	1,477 $130,000
Q3 2021 Nov 02, 2021	BUY	$74.77 - $85.47 $2,392 - $2,735	32 Added 4.6%	727 $56,000
Q2 2021 Aug 06, 2021	BUY	$75.51 - $84.79 $8,834 - $9,920	117 Added 20.24%	695 $58,000
Q4 2020 Feb 02, 2021	SELL	$72.61 - $90.2 $9,076 - $11,275	-125 Reduced 17.78%	578 $51,000
Q3 2020 Oct 27, 2020	BUY	$71.87 - $131.03 $15,883 - $28,957	221 Added 45.85%	703 $53,000
Q2 2020 Jul 16, 2020	BUY	$79.55 - $124.22 $5,966 - $9,316	75 Added 18.43%	482 $59,000
Q1 2020 Apr 27, 2020	BUY	$71.37 - $96.85 $2,355 - $3,196	33 Added 8.82%	407 $34,000
Q3 2019 Nov 01, 2019	BUY	$67.4 - $85.11 $1,415 - $1,787	21 Added 5.95%	374 $25,000
Q2 2019 Aug 05, 2019	SELL	$80.35 - $93.9 $5,222 - $6,103	-65 Reduced 15.55%	353 $30,000
Q1 2019 May 01, 2019	SELL	$84.2 - $98.62 $4,799 - $5,621	-57 Reduced 12.0%	418 $37,000
Q4 2018 Feb 05, 2019	SELL	$80.14 - $106.07 $240,660 - $318,528	-3,003 Reduced 86.34%	475 $40,000
Q3 2018 Nov 01, 2018	BUY	$93.92 - $105.72 $46,960 - $52,860	500 Added 16.79%	3,478 $337,000
Q2 2018 Jul 30, 2018	BUY	$76.01 - $99.03 $151,487 - $197,366	1,993 Added 202.34%	2,978 $280,000
Q1 2018 May 08, 2018	SELL	$77.67 - $92.63 $3,961 - $4,724	-51 Reduced 4.92%	985 $80,000
Q4 2017 Feb 13, 2018	BUY	$80.76 - $95.13 $3,553 - $4,185	44 Added 4.44%	1,036 $92,000
Q3 2017 Nov 15, 2017	BUY	$80.6 - $94.95 $79,955 - $94,190	992 New	992 $80,000
Q3 2017 Nov 14, 2017	SELL	$80.6 - $94.95 $82,856 - $97,608	-1,028 Closed	0 $0
Q2 2017 Aug 07, 2017	BUY	N/A	1,028	1,028 $90,000

Others Institutions Holding BMRN

# of Institutions

633

Shares Held

184M

Call Options Held

Put Options Held

1.67M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.7B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.

Account

Parallel Advisors, LLC Biomarin Pharmaceutical Inc Transaction History